Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
Clinical trial NCT06868836 · RECRUITING
Trial details
- NCT number
- NCT06868836
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-03-30
- Primary completion
- 2026-09-04
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.